Soleno Therapeutics, Inc.

NasdaqCM SLNO

Soleno Therapeutics, Inc. Total Assets for the quarter ending September 30, 2024: USD 296.71 M

Soleno Therapeutics, Inc. Total Assets is USD 296.71 M for the quarter ending September 30, 2024, a 366.90% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Soleno Therapeutics, Inc. Total Assets for the quarter ending September 30, 2023 was USD 63.55 M.
Soleno Therapeutics, Inc. Total Assets for the quarter ending September 30, 2021 was USD 42.56 M, a -40.70% change year over year.
Soleno Therapeutics, Inc. Total Assets for the quarter ending September 30, 2020 was USD 71.78 M.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

NasdaqCM: SLNO

Soleno Therapeutics, Inc.

CEO	Dr. Anish Bhatnagar M.D.
IPO Date	Nov. 13, 2014
Location	United States
Headquarters	203 Redwood Shores Parkway
Employees	33
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Key trends

Past 5 years